Shire Sues Impax, Watson Over Generic Intuniv

Law360, New York (December 3, 2010, 8:01 PM EST) -- Irish pharmaceutical maker Shire PLC is fighting yet again to protect sales of its attention deficit hyperactivity disorder drug Intuniv, filing a suit against Impax Laboratories Inc. and Watson Pharmaceuticals Inc. alleging that their attempt to market a generic version of the drug amounts to patent infringement.

Shire LLC, a subsidiary of the drug maker, lodged the suit Thursday in the U.S. District Court for the Northern District of California, alleging that the generics manufacturers are violating three patents for guanfacine hydrochloride extended-release tablets, sold under...
To view the full article, register now.